PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 20, 2012--
Pharmaceuticals, Inc (Nasdaq: PCRX) today announced that financial
results for the company's fourth quarter and year ended Dec. 31, 2011,
will be released before the market opens on Tuesday, March 27, 2012. The
Pacira management team will host a conference call to discuss the
company's financial results and recent and upcoming developments on
Tuesday, March 27, 2012, at 9 a.m. ET. The call can be accessed by
dialing 1-888-396-2356 (domestic) or 1-617-847-8709 (international) five
minutes prior to the start of the call and providing the passcode
A replay of the call will be available approximately two hours after the
completion of the call and can be accessed by dialing 1-888-286-8010
(domestic) or 1-617-801-6888 (international), and providing the passcode
50230808. The replay of the call will be available for two weeks from
the date of the live call.
The live, listen-only webcast of the conference call can be accessed by
visiting the investors section of the company's website at investor.pacira.com.
A replay of the webcast will be archived on the Pacira website for two
weeks following the call.
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) is an emerging specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company's current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable suspension),
was approved for administration into the surgical site to produce
postsurgical analgesia by the U.S. Food and Drug Administration in
October 2011. EXPAREL and two other commercially available products
utilize the Pacira proprietary product delivery technology DepoFoam®, a
unique platform that encapsulates drugs without altering their molecular
structure and then releases them over a desired period of time.
Additional information about Pacira is available at http://www.pacira.com.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about EXPAREL's potential and
the expected timing of commercial launch, and other statements
containing the words "believes," "anticipates," "plans," "expects," and
similar expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including risks relating to: the success of our sales and manufacturing
efforts in support of the planned commercial launch of EXPAREL; the rate
and degree of market acceptance of EXPAREL; the size and growth of the
potential markets for EXPAREL and our ability to serve those markets;
our commercialization and marketing capabilities; and other factors
discussed in the "Risk Factors" section of our final prospectus related
to our public offering filed with the Securities and Exchange Commission
on November 16, 2011, and in other filings that we periodically make
with the SEC. In addition, the forward-looking statements included in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we specifically
disclaim any obligation to do so. These forward-looking statements
should not be relied upon as representing our views as of any date
subsequent to the date of this press release.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, Chief Financial